RET and medullary thyroid gland carcinoma: In the MTC setting in the US, selpercatinib or pralsetinib may be considered for systemic therapy in adults and paediatric patients (aged ≥12 years) with advanced, but not pralsetinib, or metastatic RET-mutant disease (74, 75; in Europe, selpercatinib is approved for RET-mutant MTC in this population (76).